Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637767 | 0.91 | APP (0.47) | CHRNB2CHRNA4TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2656538 | 0.84 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL29402916 | 0.84 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL16536086 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4NPC1MAPTRAB9A | |
| SCHEMBL3002601 | 0.82 | ALDH1A1 (0.47) | CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL22117617 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL20577124 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL20577017 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL256095 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4MAPK1NPC1MAPT | |
| SCHEMBL15841452 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CHRNB2 3537/4885CHRNA4 4023/4885TSHR 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.